AZD-5423

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H21F4N3O3
Molecular Weight	487.4462
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(=CC=C1)[C@@H](OC2=CC3=C(C=C2)N(N=C3)C4=CC=C(F)C=C4)[C@H](C)NC(=O)C(F)(F)F

InChI

InChIKey=FCNQMDSJHADDFT-WNSKOXEYSA-N

InChI=1S/C25H21F4N3O3/c1-15(31-24(33)25(27,28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15,23H,1-2H3,(H,31,33)/t15-,23-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28281196 | https://clinicaltrials.gov/ct2/show/NCT01225549 | https://adisinsight.springer.com/drugs/800031497

AZD5423, a non-steroidal glucocorticoid receptor agonist, was participated in clinical trials phase II for treatment of Asthma, and Chronic Obstructive Pulmonary Disease. However, the development of the product was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423).	2013 Sep	23865465

Patents

Sample Use Guides

In Vivo Use Guide

AZD5423 75ug Suspension for nebulisation once daily 7 days

Route of Administration: Other

Name

Type

Language

AZD-5423

Common Name

English

AZD 5423 [WHO-DD]

Common Name

English

AZD5423

Code

English

2,2,2-TRIFLUORO-N-((1R,2S)-1-(1-(4-FLUOROPHENYL)INDAZOL-5-YL)OXY-1-(3-METHOXYPHENYL)PROPAN-2-YL)ACETAMIDE

Systematic Name

English

Code System Code Type Description

DRUG BANK

DB12280